APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripherally Acting Anti-Obesity Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peripherally Acting Anti-Obesity Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025191 pages

Choose your research edition.

Industry ResearchPeripherally Acting Anti-Obesity Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripherally Acting Anti-Obesity Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Peripherally Acting Anti-Obesity Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripherally Acting Anti-Obesity Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripherally Acting Anti-Obesity Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peripherally Acting Anti-Obesity Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peripherally Acting Anti-Obesity Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peripherally Acting Anti-Obesity Drug include Novo Nordisk A/S, Pfizer Inc., GlaxoSmithKline plc, Vivus LLC., Rhythm Pharmaceuticals, KVK Tech Inc., Gelesis Holdings, Currax Pharmaceuticals LLC and CHEPLAPHARM Arzneimittel GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peripherally Acting Anti-Obesity Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peripherally Acting Anti-Obesity Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peripherally Acting Anti-Obesity Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peripherally Acting Anti-Obesity Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Peripherally Acting Anti-Obesity Drug Segment by Company

Novo Nordisk A/S

Pfizer Inc.

GlaxoSmithKline plc

Vivus LLC.

Rhythm Pharmaceuticals

KVK Tech Inc.

Gelesis Holdings

Currax Pharmaceuticals LLC

CHEPLAPHARM Arzneimittel GmbH

Boehringer Ingelheim International GmbH

Peripherally Acting Anti-Obesity Drug Segment by Type

Prescription Drugs

Non-prescription Drugs

Peripherally Acting Anti-Obesity Drug Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Peripherally Acting Anti-Obesity Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripherally Acting Anti-Obesity Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripherally Acting Anti-Obesity Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripherally Acting Anti-Obesity Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peripherally Acting Anti-Obesity Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peripherally Acting Anti-Obesity Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Peripherally Acting Anti-Obesity Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Peripherally Acting Anti-Obesity Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Peripherally Acting Anti-Obesity Drug Industry Trends Table 2. Peripherally Acting Anti-Obesity Drug Industry Drivers Table 3. Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges Table 4. Peripherally Acting Anti-Obesity Drug Industry Restraints Table 5. Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Peripherally Acting Anti-Obesity Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Manufacturers Table 9. Global Peripherally Acting Anti-Obesity Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Peripherally Acting Anti-Obesity Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Peripherally Acting Anti-Obesity Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Peripherally Acting Anti-Obesity Drug Manufacturers, Product Type & Application Table 13. Global Peripherally Acting Anti-Obesity Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Peripherally Acting Anti-Obesity Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Prescription Drugs Table 17. Major Manufacturers of Non-prescription Drugs Table 18. Global Peripherally Acting Anti-Obesity Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 20. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 21. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2026) Table 22. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2027-2032) Table 23. Global Peripherally Acting Anti-Obesity Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2026) & (k units) Table 25. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2027-2032) & (k units) Table 26. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2026) Table 27. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Online Pharmacies Table 29. Major Manufacturers of Hospital Pharmacies Table 30. Major Manufacturers of Retail Pharmacies Table 31. Global Peripherally Acting Anti-Obesity Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 33. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 34. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2026) Table 35. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2027-2032) Table 36. Global Peripherally Acting Anti-Obesity Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2026) & (k units) Table 38. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2027-2032) & (k units) Table 39. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2026) Table 40. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2027-2032) Table 41. Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2026) & (k units) Table 43. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2021-2026) Table 44. Global Peripherally Acting Anti-Obesity Drug Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Peripherally Acting Anti-Obesity Drug Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 48. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 49. Europe Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 51. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 58. Global Peripherally Acting Anti-Obesity Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2021-2026) Table 62. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2027-2032) Table 63. Novo Nordisk A/S Company Information Table 64. Novo Nordisk A/S Business Overview Table 65. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio Table 67. Novo Nordisk A/S Recent Development Table 68. Pfizer Inc. Company Information Table 69. Pfizer Inc. Business Overview Table 70. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 72. Pfizer Inc. Recent Development Table 73. GlaxoSmithKline plc Company Information Table 74. GlaxoSmithKline plc Business Overview Table 75. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio Table 77. GlaxoSmithKline plc Recent Development Table 78. Vivus LLC. Company Information Table 79. Vivus LLC. Business Overview Table 80. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 82. Vivus LLC. Recent Development Table 83. Rhythm Pharmaceuticals Company Information Table 84. Rhythm Pharmaceuticals Business Overview Table 85. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio Table 87. Rhythm Pharmaceuticals Recent Development Table 88. KVK Tech Inc. Company Information Table 89. KVK Tech Inc. Business Overview Table 90. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 92. KVK Tech Inc. Recent Development Table 93. Gelesis Holdings Company Information Table 94. Gelesis Holdings Business Overview Table 95. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio Table 97. Gelesis Holdings Recent Development Table 98. Currax Pharmaceuticals LLC Company Information Table 99. Currax Pharmaceuticals LLC Business Overview Table 100. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio Table 102. Currax Pharmaceuticals LLC Recent Development Table 103. CHEPLAPHARM Arzneimittel GmbH Company Information Table 104. CHEPLAPHARM Arzneimittel GmbH Business Overview Table 105. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 107. CHEPLAPHARM Arzneimittel GmbH Recent Development Table 108. Boehringer Ingelheim International GmbH Company Information Table 109. Boehringer Ingelheim International GmbH Business Overview Table 110. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 112. Boehringer Ingelheim International GmbH Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Peripherally Acting Anti-Obesity Drug Distributors List Table 116. Peripherally Acting Anti-Obesity Drug Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Peripherally Acting Anti-Obesity Drug Product Image Figure 2. Global Peripherally Acting Anti-Obesity Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peripherally Acting Anti-Obesity Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Peripherally Acting Anti-Obesity Drug Sales (2021-2032) & (k units) Figure 5. Global Peripherally Acting Anti-Obesity Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Peripherally Acting Anti-Obesity Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Prescription Drugs Image Figure 9. Non-prescription Drugs Image Figure 10. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Peripherally Acting Anti-Obesity Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2032) Figure 13. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2032) Figure 16. Online Pharmacies Image Figure 17. Hospital Pharmacies Image Figure 18. Retail Pharmacies Image Figure 19. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Peripherally Acting Anti-Obesity Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2032) Figure 22. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 27. U.S. Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 32. Germany Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 39. China Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2021-2032) Figure 47. Brazil Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Peripherally Acting Anti-Obesity Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Peripherally Acting Anti-Obesity Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Figure 58. North America Peripherally Acting Anti-Obesity Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Figure 60. Europe Peripherally Acting Anti-Obesity Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Peripherally Acting Anti-Obesity Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Peripherally Acting Anti-Obesity Drug Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Peripherally Acting Anti-Obesity Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drugs
  • Non-prescription Drugs
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Novo Nordisk A/S
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Vivus LLC.
  • Rhythm Pharmaceuticals
  • KVK Tech Inc.
  • Gelesis Holdings
  • Currax Pharmaceuticals LLC
  • CHEPLAPHARM Arzneimittel GmbH
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peripherally Acting Anti-Obesity Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peripherally Acting Anti-Obesity Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Peripherally Acting Anti-Obesity Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Peripherally Acting Anti-Obesity Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Peripherally Acting Anti-Obesity Drug Market Dynamics
  1. 2.1 Peripherally Acting Anti-Obesity Drug Industry Trends
  2. 2.2 Peripherally Acting Anti-Obesity Drug Industry Drivers
  3. 2.3 Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges
  4. 2.4 Peripherally Acting Anti-Obesity Drug Industry Restraints
3 Peripherally Acting Anti-Obesity Drug Market by Manufacturers
  1. 3.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Peripherally Acting Anti-Obesity Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Peripherally Acting Anti-Obesity Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Peripherally Acting Anti-Obesity Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peripherally Acting Anti-Obesity Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Peripherally Acting Anti-Obesity Drug Manufacturers, Product Type & Application
  7. 3.7 Global Peripherally Acting Anti-Obesity Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peripherally Acting Anti-Obesity Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peripherally Acting Anti-Obesity Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peripherally Acting Anti-Obesity Drug Tier 1, Tier 2, and Tier 3
4 Peripherally Acting Anti-Obesity Drug Market by Type
  1. 4.1 Peripherally Acting Anti-Obesity Drug Type Introduction
  2. 4.1.1 Prescription Drugs
  3. 4.1.2 Non-prescription Drugs
  4. 4.2 Global Peripherally Acting Anti-Obesity Drug Sales by Type
  5. 4.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032)
  7. 4.2.3 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global Peripherally Acting Anti-Obesity Drug Revenue by Type
  9. 4.3.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2032)
5 Peripherally Acting Anti-Obesity Drug Market by Application
  1. 5.1 Peripherally Acting Anti-Obesity Drug Application Introduction
  2. 5.1.1 Online Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Peripherally Acting Anti-Obesity Drug Sales by Application
  6. 5.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Peripherally Acting Anti-Obesity Drug Revenue by Application
  10. 5.3.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2032)
6 Global Peripherally Acting Anti-Obesity Drug Sales by Region
  1. 6.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Peripherally Acting Anti-Obesity Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Peripherally Acting Anti-Obesity Drug Revenue by Region
  1. 7.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Region
  2. 7.1.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Peripherally Acting Anti-Obesity Drug Revenue (2021-2032)
  8. 7.2.2 North America Peripherally Acting Anti-Obesity Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Peripherally Acting Anti-Obesity Drug Revenue (2021-2032)
  11. 7.3.2 Europe Peripherally Acting Anti-Obesity Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk A/S
  2. 8.1.1 Novo Nordisk A/S Company Information
  3. 8.1.2 Novo Nordisk A/S Business Overview
  4. 8.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio
  6. 8.1.5 Novo Nordisk A/S Recent Developments
  7. 8.2 Pfizer Inc.
  8. 8.2.1 Pfizer Inc. Company Information
  9. 8.2.2 Pfizer Inc. Business Overview
  10. 8.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  12. 8.2.5 Pfizer Inc. Recent Developments
  13. 8.3 GlaxoSmithKline plc
  14. 8.3.1 GlaxoSmithKline plc Company Information
  15. 8.3.2 GlaxoSmithKline plc Business Overview
  16. 8.3.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio
  18. 8.3.5 GlaxoSmithKline plc Recent Developments
  19. 8.4 Vivus LLC.
  20. 8.4.1 Vivus LLC. Company Information
  21. 8.4.2 Vivus LLC. Business Overview
  22. 8.4.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio
  24. 8.4.5 Vivus LLC. Recent Developments
  25. 8.5 Rhythm Pharmaceuticals
  26. 8.5.1 Rhythm Pharmaceuticals Company Information
  27. 8.5.2 Rhythm Pharmaceuticals Business Overview
  28. 8.5.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio
  30. 8.5.5 Rhythm Pharmaceuticals Recent Developments
  31. 8.6 KVK Tech Inc.
  32. 8.6.1 KVK Tech Inc. Company Information
  33. 8.6.2 KVK Tech Inc. Business Overview
  34. 8.6.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  36. 8.6.5 KVK Tech Inc. Recent Developments
  37. 8.7 Gelesis Holdings
  38. 8.7.1 Gelesis Holdings Company Information
  39. 8.7.2 Gelesis Holdings Business Overview
  40. 8.7.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio
  42. 8.7.5 Gelesis Holdings Recent Developments
  43. 8.8 Currax Pharmaceuticals LLC
  44. 8.8.1 Currax Pharmaceuticals LLC Company Information
  45. 8.8.2 Currax Pharmaceuticals LLC Business Overview
  46. 8.8.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio
  48. 8.8.5 Currax Pharmaceuticals LLC Recent Developments
  49. 8.9 CHEPLAPHARM Arzneimittel GmbH
  50. 8.9.1 CHEPLAPHARM Arzneimittel GmbH Company Information
  51. 8.9.2 CHEPLAPHARM Arzneimittel GmbH Business Overview
  52. 8.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  54. 8.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments
  55. 8.10 Boehringer Ingelheim International GmbH
  56. 8.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 8.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 8.10.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  60. 8.10.5 Boehringer Ingelheim International GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peripherally Acting Anti-Obesity Drug Value Chain Analysis
  2. 9.1.1 Peripherally Acting Anti-Obesity Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peripherally Acting Anti-Obesity Drug Production Mode & Process
  6. 9.2 Peripherally Acting Anti-Obesity Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peripherally Acting Anti-Obesity Drug Distributors
  9. 9.2.3 Peripherally Acting Anti-Obesity Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst